|
Market Closed -
Nasdaq
16:00:00 2026-10-23 EDT
|
5-day change | 1st Jan Change | ||
| 6.180 USD | -3.59% |
|
-1.44% | -14.29% |
Company Valuation: Cartesian Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 107 | 460.7 | 187.5 | 187 | - | - |
| Change | - | 330.61% | -59.31% | -0.27% | - | - |
| Enterprise Value (EV) 1 | 107 | 241.5 | 62.35 | 45.98 | -102.7 | -156.3 |
| Change | - | 125.75% | -74.19% | -26.25% | -323.42% | -52.18% |
| P/E | -0.42x | -4x | -1.44x | -2.06x | -1.49x | -1.47x |
| PBR | - | - | - | - | - | - |
| PEG | - | 0x | -0.1x | 0.1x | -0x | -1.48x |
| Capitalization / Revenue | 4.11x | 11.8x | 67x | 446x | 654x | 8.48x |
| EV / Revenue | 4.11x | 6.21x | 22.3x | 110x | -360x | -7.09x |
| EV / EBITDA | - | - | - | - | - | - |
| EV / EBIT | -1.24x | -5.5x | -0.43x | -0.39x | 0.75x | 0.99x |
| EV / FCF | - | -7.37x | -0.79x | -0.42x | 0.96x | 1.31x |
| FCF Yield | - | -13.6% | -127% | -237% | 104% | 76.4% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -49.8 | -4.48 | -5.02 | -3.004 | -4.159 | -4.2 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 26 | 38.91 | 2.797 | 0.4191 | 0.2857 | 22.05 |
| EBITDA | - | -42.75 | - | - | - | - |
| EBIT 1 | -86.42 | -43.9 | -143.4 | -119.4 | -136.9 | -157.9 |
| Net income 1 | -219.7 | -77.42 | -130.3 | -88.41 | -144 | -180.4 |
| Net Debt 1 | - | -219.2 | -125.1 | -141 | -289.7 | -343.3 |
| Reference price 2 | 20.682 | 17.910 | 7.210 | 6.180 | 6.180 | 6.180 |
| Nbr of stocks (in thousands) | 5,173 | 25,725 | 26,004 | 30,255 | - | - |
| Announcement Date | 3/7/24 | 3/13/25 | 3/9/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.06x | 109.7x | - | - | 187M | |
| 18.83x | 6.63x | 13.18x | 1.58% | 64.69B | |
| 30.16x | 8x | 26.2x | 0.05% | 54.78B | |
| 36.79x | 6.53x | 19.51x | 0.88% | 53.49B | |
| 35.59x | 3.45x | 14.87x | -.--% | 45.98B | |
| 49.71x | 5.74x | 31.52x | -.--% | 42.94B | |
| -19.41x | 187.75x | -20.66x | -.--% | 40.08B | |
| 28.93x | 8.21x | 21.27x | 0.37% | 33.52B | |
| 27.67x | 5.83x | 15.12x | -.--% | 23.97B | |
| 32.66x | 5.97x | 20.09x | -.--% | 23.67B | |
| Average | 23.89x | 34.78x | 15.68x | 0.32% | 38.33B | |
| Weighted average by Cap. | 26.71x | 25.37x | 15.90x | 0.43% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RNAC Stock
- Valuation Cartesian Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
